Statin use is not associated with improved progression free survival in cetuximab Treated KRAS mutant metastatic colorectal cancer patients: Results from the CAIRO2 study

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Krens, Lisanne L ^a   Simkens, Lieke H J ^b   Baas, Jara M ^a   Koomen, Els R ^a   Gelderblom, Hans ^a   Punt, Cornelis J A ^b   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXALIPLATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ADOLESCENT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; ADULT; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84910651202     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112201     Document Type: Article

References (21)

1. Eisenberg DA (1998) Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 104: 2S-5S.
2. Nielsen SF, Nordestgaard BG, Bojesen S.E. (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367: 1792-1802.
3. Konstantinopoulos PA, Karamouzis MV, Papavassiliou A.G. (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555.
4. Tol J, Punt C.J. (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32: 437-453.
5. Lievre A, Bachet JB, Le C.D., Boige V., Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
6. Douillard JY, Oliner KS, Siena S, Tabernero J., Burkes R, et al. (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.
7. Krens LL, Baas JM, Gelderblom H, Guchelaar H.J. (2010) Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today 15: 502-516.
8. Tol J, Koopman M, Cats A., Rodenburg CJ, Creemers GJ, et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572.
9. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar H.J. (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641.
10. Chan KK, Oza AM, Siu L.L. (2003) The statins as anticancer agents. Clin Cancer Res 9: 10-19.
11. Maciejak A, Leszczynska A, Warchol I., Gora M, Kaminska J, et al (2013) The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. BMC Biotechnol 13: 68.
12. Gonyeau MJ (2014) The spectrum of statin therapy in cancer patients: is there a need for further investigation? Curr Atheroscler Rep 16: 383.
13. Scartozzi M, Galizia E, Chiorrini S., Giampieri R, Berardi R, et al (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20: 227-230.
14. Liu Y, Tang W, Wang J., Xie L, Li T, et al (2013) Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control.
15. Graaf MR, Beiderbeck AB, Egberts A.C., Richel DJ, Guchelaar H.J. (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394.
16. Mace AG, Gantt GA, Skacel M, Pai R., Hammel JP, et al. (2013) Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56: 1217-1227.
17. Ng K, Ogino S, Meyerhardt J.A., Chan JA, Chan AT, et al. (2011) Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 103: 1540-1551.
18. Lee J, Jung KH, Park Y.S., Ahn JB, Shin SJ, et al. (2009) Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 64: 657-663.
19. Katz MS, Minsky BD, Saltz L.B., Riedel E., Chessin DB, et al. (2005) Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62: 1363-1370.
20. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner B.A., Taylor CW, et al. (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45: 895-903.
21. Siddiqui AA, Nazario H, Mahgoub A., Patel M, Cipher D, et al (2009) For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 54: 1307-1311.